Home › 🔬 PubMed Lab

🔬 PubMed Lab Free · No signup

Search PubMed with a plain-English research question, then chat with an AI about any paper. Powered by Claude (Anthropic) + NIH PubMed E-utilities.

10 of ~143 matches · 499 ms

  1. #1 Diabetes (2014)

    GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans.

    Liselotte van Bloemendaal, Richard G IJzerman, Jennifer S Ten Kulve et al.

    Gut-derived hormones, such as GLP-1, have been proposed to relay information to the brain to regulate appetite. GLP-1 receptor agonists, currently used for the treatment of type 2 diabetes (T2DM), improve glycemic control and stimulate satiety, leading to decreases in food intake and body weight. We hypothesized that food intake reduction after GLP-1 receptor activation is mediated through appetit…

    🔗 Open on PubMed
  2. #2 Endocrinology (2025)

    GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder.

    Elisabet Jerlhag

    Glucagon-like peptide-1 (GLP-1) is abundant in the circulation, and it is well-known to regulate glucose homeostasis, feeding, and body weight. GLP-1 receptor agonists are therefore approved for treating type 2 diabetes and obesity. However, more recent research has demonstrated that GLP-1 acts within the brain to modulate reward responses, thereby highlighting GLP-1 as a potential target for addi…

    🔗 Open on PubMed
  3. #3 JCI insight (2020)

    Semaglutide lowers body weight in rodents via distributed neural pathways.

    Sanaz Gabery, Casper G Salinas, Sarah J Paulsen et al.

    Semaglutide, a glucagon-like peptide 1 (GLP-1) analog, induces weight loss, lowers glucose levels, and reduces cardiovascular risk in patients with diabetes. Mechanistic preclinical studies suggest weight loss is mediated through GLP-1 receptors (GLP-1Rs) in the brain. The findings presented here show that semaglutide modulated food preference, reduced food intake, and caused weight loss without d…

    🔗 Open on PubMed
  4. #4 International journal of molecular sciences (2022)

    GLP-1a: Going beyond Traditional Use.

    Lucas Fornari Laurindo, Sandra Maria Barbalho, Elen Landgraf Guiguer et al.

    Glucagon-like peptide-1 (GLP-1) is a human incretin hormone derived from the proglucagon molecule. GLP-1 receptor agonists are frequently used to treat type 2 diabetes mellitus and obesity. However, the hormone affects the liver, pancreas, brain, fat cells, heart, and gastrointestinal tract. The objective of this study was to perform a systematic review on the use of GLP-1 other than in treating d…

    🔗 Open on PubMed
  5. #5 The journal of physiological sciences : JPS (2024)

    Satiety: a gut-brain-relationship.

    Ghinwa M Barakat, Wiam Ramadan, Ghaith Assi et al.

    Many hormones act on the hypothalamus to control hunger and satiety through various pathways closely associated with several factors. When food is present in the gastro intestinal (GI) tract, enteroendocrine cells (EECs) emit satiety signals such as cholecystokinin (CCK), glucagon like peptide-1 (GLP-1) and peptide YY (PYY), which can then communicate with the vagus nerve to control food intake. M…

    🔗 Open on PubMed
  6. #6 The Journal of endocrinology (2024)

    The emerging role of glucagon-like peptide 1 in binge eating.

    Katherine N Balantekin, Martin J Kretz, Elizabeth G Mietlicki-Baase et al.

    Binge eating is a central component of two clinical eating disorders: binge eating disorder and bulimia nervosa. However, the large treatment gap highlights the need to identify other strategies to decrease binge eating. Novel pharmacotherapies may be one such approach. Glucagon-like peptide-1 (GLP-1) is an intestinal and brain-derived neuroendocrine signal with a critical role in promoting glycem…

    🔗 Open on PubMed
  7. #7 Frontiers in pharmacology (2025)

    The potential role of GLP-1 receptor agonists in substance use disorders - a systematic review.

    K M Völker, B L H Prechtl, N L Bormann et al.

    Substance use disorders (SUDs) remain a major global health challenge with limited pharmacological treatment options and high relapse rates. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for type 2 diabetes and obesity, have recently gained attention for their potential effects on addictive behaviors. Preclinical and early clinical studies suggest that GLP-1RAs modulat…

    🔗 Open on PubMed
  8. #8 JCI insight (2022)

    Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial.

    Mette Kruse Klausen, Mathias Ebbesen Jensen, Marco Møller et al.

    BackgroundAlcohol use disorder (AUD) is a chronic, relapsing brain disorder that accounts for 5% of deaths annually, and there is an urgent need to develop new targets for therapeutic intervention. The glucagon-like peptide-1 (GLP-1) receptor agonist exenatide reduces alcohol consumption in rodents and nonhuman primates, but its efficacy in patients with AUD is unknown.MethodsIn a randomized, doub…

    🔗 Open on PubMed
  9. #9 Progress in cardiovascular diseases (2025)

    Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy.

    James H O'Keefe, W Grant Franco, Evan L O'Keefe et al.

    American culture encourages overconsumption, fueled by ubiquitous availability and pervasive marketing of ultra-processed foods and other addictive substances. This chronic overindulgence has contributed to rising rates of obesity, type 2 diabetes (T2D), substance abuse, mental health disorders and premature mortality. Glucose-like peptide-1 agonists (GLP-1RAs) affect the brain's reward pathway th…

    🔗 Open on PubMed
  10. #10 Journal of psychiatric research (2026)

    The dual role of GLP-1 receptor agonists in weight management and eating disorders: Potential benefits and risks.

    Aleksandra Leziak, Klaudia Kochman, Piotr Kocełak et al.

    Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as effective therapies for type 2 diabetes mellitus (T2DM) and obesity, as they improve glycaemic control, promote weight loss and modulate metabolic processes. However, their potent appetite-suppressing effects pose a complex challenge in patients with or at risk of eating disorders (EDs). This narrative review examines the dual ro…

    🔗 Open on PubMed

❓ How it works

What does this do?

You type a research question in English. We query the NIH PubMed database and show the top 10 most relevant. Click "💬 Chat with AI" below any paper to ask questions about its methods, findings, and limitations — inline, right below the paper.

Is this free?

Yes, and no signup is required. Funded by affiliate links + ads elsewhere on the site.

Any usage limit?

3 chat messages per browser per day (cost control). Search itself is unlimited.

Do you store my queries?

Queries appear in server logs (retained ~14 days for abuse prevention) and are sent to Anthropic's Claude API for chat (Anthropic's terms apply). Not sold to third parties.

Medical disclaimer?

The AI answers are general education, not medical advice. Consult a qualified professional for any health decision. See our editorial policy.